Skip to main content
Article thumbnail
Location of Repository

Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events

By Sylvester KW, Cheng JW and Mehra MR

Abstract

Katelyn W Sylvester,1 Judy WM Cheng,1,3 Mandeep R Mehra2,41Department of Pharmacy, 2Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; 3Massachusetts College of Pharmacy and Health Sciences, Boston, MA, 4Harvard Medical School, Boston MA, USAAbstract: Low dose aspirin therapy plays a fundamental role in both the primary and secondary prevention of cardiovascular events. Although the evidence using low dose aspirin for secondary prevention is well-established, the decision to use aspirin for primary prevention is based on an evaluation of the patient’s risk of cardiovascular events compared to their risk of adverse events, such as bleeding. In addition to the risk of bleeding associated with long term aspirin administration, upper gastrointestinal side effects, such as dyspepsia often lead to discontinuation of therapy, which places patients at an increased risk for cardiovascular events. One option to mitigate adverse events and increase adherence is the addition of esomeprazole to the medication regimen. This review article provides an evaluation of the literature on the concomitant use of aspirin and esomeprazole available through February 2013. The efficacy, safety, tolerability, cost effectiveness, and patient quality of life of this regimen is discussed. A summary of the pharmacokinetic and pharmacodynamic interactions between aspirin and esomeprazole, as well as other commonly used cardiovascular medications are also reviewed. The addition of esomeprazole to low dose aspirin therapy in patients at high risk of developing gastric ulcers for the prevention of cardiovascular disease, significantly reduced their risk of ulcer development. Pharmacokinetic and pharmacodynamic studies suggested that esomeprazole did not affect the pharmacokinetic parameters or the antiplatelet effects of aspirin. Therefore, for those patients who are at a high risk of developing a gastrointestinal ulcer, the benefit of adding esomeprazole likely outweighs the risks of longer term proton pump inhibitor use, and the combination can be recommended. Administering the two agents separately may also be more economical. On the other hand, for those patients at lower risk of developing a gastrointestinal ulcer, both the additional risk and cost make the inclusion of a proton pump inhibitor unwarranted.Keywords: aspirin, esomeprazole, proton pump inhibitors, cardiovascular event preventio

Topics: Diseases of the circulatory (Cardiovascular) system, RC666-701, Specialties of internal medicine, RC581-951, Internal medicine, RC31-1245, Medicine, R, DOAJ:Cardiovascular, DOAJ:Medicine (General), DOAJ:Health Sciences
Publisher: Dove Medical Press
Year: 2013
OAI identifier: oai:doaj.org/article:79d60d210bca4eb498628cbcae90a9b6
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/1178-2048 (external link)
  • https://doaj.org/toc/1176-6344 (external link)
  • http://www.dovepress.com/esome... (external link)
  • https://doaj.org/article/79d60... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.